Ember Therapeutics Inc
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport'… Read more
Market Cap & Net Worth: Ember Therapeutics Inc (EMBT)
Ember Therapeutics Inc (PINK:EMBT) has a market capitalization of $4.00K ($4.00K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #51407 globally and #16101 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ember Therapeutics Inc's stock price $0.00 by its total outstanding shares 40000000 (40.00 Million).
Ember Therapeutics Inc Market Cap History: 2021 to 2025
Ember Therapeutics Inc's market capitalization history from 2021 to 2025. Data shows change from $12.00K to $4.00K (-88.64% CAGR).
Ember Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ember Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EMBT by Market Capitalization
Companies near Ember Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Ember Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Ember Therapeutics Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Ember Therapeutics Inc's market cap moved from $12.00K to $ 4.00K, with a yearly change of -88.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.00K | 0.00% |
| 2024 | $4.00K | 0.00% |
| 2023 | $4.00K | 0.00% |
| 2022 | $4.00K | -66.67% |
| 2021 | $12.00K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ember Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.00K USD |
| MoneyControl | $4.00K USD |
| MarketWatch | $4.00K USD |
| marketcap.company | $4.00K USD |
| Reuters | $4.00K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.